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Abstract 
BACKGROUND: Chronic hepatitis C virus infection represents a more frequent cause of liver cirrhosis and 
hepatocellular carcinoma. Statins, inhibit HCV replication in vitro, enhance the antiviral effect of the already known 
antiviral drugs and reduce their resistance. 
AIM: To determine the impact of additional therapy (treatment with Atorvastatin 20 mg) to the standard antiviral 
therapy (pegylated interferon alpha-peg-IFN α and ribavirin) on achieving sustained virological response (SVR). 
MATERIAL AND METHODS: In the study which is comparative, open-label, prospective-retrospective, 70 
patients diagnosed with chronic hepatitis C virus infection who met criteria for treatment with standard antiviral 
therapy combined with anti-lipemic therapy (Atorvastatin 20 mg) were included. Patients in the study were divided 
into two groups: one group of 35 patients receiving combination therapy (Atorvastatin + peg-IFN α + Ribavirin) 
and another group of 35 patients received only standard antiviral therapy. Those parameters were followed in all 
patients: genotyping, quantification of the virus, histological assessment of liver inflammation and fibrosis degree 
(before starting treatment), the presence of steatosis, laboratory analysis: hematology, liver, lipid and 
carbohydrate status, insulin blood level (the calculation of HOMA-IR) and body mass index (BMI) calculation. The 
overall treatment of the patients depends from the virus genotype, thus, patients with genotype 1 and 4 received 
48 weeks standard antiviral therapy, but patients with genotypes 2 and 3 received 24 weeks of antiviral therapy. 
SVR was considered an undetectable level of HCV RNA levels 24 weeks after completion of antiviral therapy. The 
results were statistically analysed, and all results for p < 0.05 were considered statistically significant. 
RESULTS: Combination therapy leads to a slightly higher percentage of SVR (85.71%) in patients with chronic 
hepatitis C versus standard therapy (74.29%), but in a group of patients with genotype 3 this rate of SVR 
amounting to 95.83%. Combination therapy leads to significant improvement of lipid and glucose status after 
treatment, and in terms of side effects, there was no appearance of serious adverse events that would be a 
reason for discontinuation of the therapy. 
CONCLUSION: Combination therapy Atorvastatin + pegylated interferon alpha + Ribavirin leads to high rate of 
SVR of 95.83% in patients with chronic hepatitis C, genotype 3. Statins can be used safely in patients with chronic 
hepatitis C. 
 
 
 
 
Introduction 
 
Hepatitis C viral (HCV) infection is one of the 
main causes of liver diseases worldwide. The severity 
of the diseases is quite different, in the spectrum from 
acute hepatitis, through liver cirrhosis to 
hepatocellular carcinoma [1]. The end stage of liver 
disease has a definite need for liver transplantation as 
the only curative method [2]. The hepatitis C virus 
uses the host's lipoprotein metabolism for its life cycle 
[3]. HCV circulates into the bloodstream as 
lipoviroparticle composed of triglyceride-rich 
lipoproteins containing both, apolipoproteins B and E, 
viral RNA, and structural nuclear viral protein [4], [5]. 
During the HCV life cycle, from the viral entry 
into the cell, until the liberation of the virions, the virus 
modulates the cellular fat metabolism [6]. To facilitate 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
2                                                                                                                                                                                                   https://www.id-press.eu/mjms/index 
 
its replication, the hepatitis C virus increases 
lipogenesis, resulting in accumulation of the 
triglycerides and the cholesterol in hepatocytes [7], 
[8]. 
Cholesterol is synthesised in hepatocytes 
through a mevalonate pathway, which is promoted by 
several enzymes, including HMG-CoA (3-hydroxy-3-
methyl-glutaryl-coenzyme A) reductase (HMGR). 
Normally, HMGR expression is consistent with the 
intracellular cholesterol level, but despite significant 
cholesterol accumulation, HMGR expression is 
substantially enhanced in the HCV-infected liver. The 
Mevalonate pathway for de novo synthesis of 
cholesterol is also responsible for the synthesis of 
farnesyl pyrophosphate and geranylgeranyl 
pyrophosphate (GGPP), which are essential for viral 
replication [9]. The hepatitis C virus induces a 
paradoxical condition in which cholesterogenesis is 
stimulated, but the current cholesterol synthesis is 
interrupted, or disturbed, by diverting to the synthesis 
of the intermediate GGPP needed for viral replication 
[10]. Due to the suppression of cholesterol synthesis, 
cholesterol levels and its fractions in HCV infected 
patients are lower. 
Statins are a class of competitive inhibitors of 
HMG-CoA reductase, which are used for controlling 
cholesterol levels in patients with hyperlipidemia, but 
have a strong pleiotropic effect, modulating the 
inflammation, the angiogenesis, the apoptosis and the 
cell growth [11], [12], [13]. It is of importance to 
emphasise the effect of statins on the inhibition of 
HCV replication, which determined their significant 
anti-HCV effect [14]. Statins block HCV replication by 
inhibiting the de novo synthesis of cholesterol and 
inhibition of geranylgeranyl pyrophosphate [15], [16]. 
Thus, statin therapy can reduce the level of HCV RNA 
in the blood despite the fact that cholesterol synthesis 
is suppressed, then it leads to a rise in cholesterol 
levels after SVR is reached, and it has also been 
observed that patients with a higher cholesterol 
baseline are more likely to respond positively to 
antiviral therapy [17], [18]. 
Several studies have shown that statins inhibit 
HCV replication in vitro, that they improve the antiviral 
activity of already known antiviral drugs and that they 
reduce their resistance [19], [20]. In vivo studies have 
shown that statin monotherapy in conventional doses 
does not inhibit HCV replication [21]. In contrast, 
statins increase the rate of sustained virologic 
response when combined with pegylated interferon 
and ribavirin [22], [23], [24]. 
In addition to the positive effect of statins, 
along with antiviral therapy with pegylated interferon 
and ribavirin over the virologic response, it should be 
noted the influence of statins on the process of 
fibrosis, thus preventing the development of a more 
advanced form of liver disease [25]. However, the 
possible protective role of the occurrence of HCC, 
although it has not been proven in randomised 
studies, should not be neglected. 
The purpose of the study is to determine the 
impact of additional therapy (atorvastatin 20 mg 
treatment) to standard antiviral therapy (Pegylated 
interferon alpha-peg-IFN α + Ribavirin) on achieving a 
sustained virologic response 
 
 
Material and Methods 
 
The study is comparative, open, 
prospectively-retrospective, which was conducted at 
the University Clinic of Gastroenterohepatology in 
Skopje in the period from 2015 to 2017. A total of 70 
patients were included with diagnosed chronic 
hepatitis C virus infection that met criteria for 
treatment with antiviral therapy in combination with 
antilipemic therapy. Patients were divided into two 
study groups: 
1. A group of 35 patients who, besides 
antiviral therapy with peg-IFN α and Ribavirin, 
received additional antilipemic therapy Atorvastatin 20 
mg, orally once daily for the entire duration of the 
study. 
2. A group of 35 patients who received 
standard antiviral therapy with peg-IFN α 
subcutaneously administered once a week (180 μg for 
peg-IFN α2a and 1.5 μg/kg for peg-IFN α2b), for a 
duration of 24 or 48 weeks depending on the 
genotype (48 weeks for genotype 1 and 4, and 24 
weeks for genotype 2 and 3) and Ribavirin 
administered orally at a daily dose of 800 to 1200 mg 
depending on the genotype and body weight. 
 
Inclusion criteria 
Patients aged over 18 years, regardless of 
gender and race, verified C hepatitis virus infection 
(seropositive HCV patients, and PCR-confirmed HCV 
RNA positivity), naive or pre-treated patients with 
standard antiviral therapy, respondents with ability to 
follow the instructions given by the expert and meet 
the requirements of the provided study treatment, 
signed informed consent. 
 
Exclusion criteria 
Active intravenous drug addicts, the presence 
of other types of viruses (HBV or HIV), dialysis 
patients, patients with other etiology of liver disease 
(autoimmune hepatitis, Wilson's disease, 
haemochromatosis, primary biliary cirrhosis, primary 
sclerosing cholangitis, α1 antitrypsin deficiency), 
hepatic decompensation, previous liver 
transplantation, alcohol abuse (> 20 g/day), presence 
of HCC and allergy data on the above-mentioned 
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drugs. 
The following examinations were made in all 
patients: - genotyping (determination the genotype of 
the virus); - quantification of HCV RNA (viral load or 
number of copies); - liver biopsy under ultrasound 
control for histological assessment of the degree of 
inflammation and fibrosis, using the Knodel scale and 
HAI (histological activity index). According to the 
presence of fibrotic changes in the liver, patients were 
divided into three groups: Group 1 - the absence of 
fibrosis; Group 2 - the presence of fibrosis; and Group 
3 - verified liver cirrhosis; - ultrasound examination of 
the abdomen for assessment of hepatic steatosis. 
Estimation of steatosis is done before starting with 
antiviral therapy and after completing the therapy. In 
addition, steatosis was graded from 0-2 degrees: 0 - 
absence of steatosis; degree 1- mild steatosis, with 
quite easily increased echogenicity of the liver 
parenchyma and clear visualization of the diaphragm 
and walls of the intrahepatic vessels; and degree 2 - 
severe steatosis with impaired or no visualization of 
the diaphragm and blood vessel walls; - laboratory 
analysis (haematological, hepatological, lipid, glucid 
status, insulinemia with HOMA-IR calculation); - 
autoantibodies to exclude autoimmune liver disease; - 
thyroid status (TSH, fT4); - Body Mass Index (BMI) 
calculation, according to the formula: weight in 
kg/(height in meters)
2
. 
All patients were evaluated for the virological 
response achieved (12 weeks after initiation of 
treatment, at the end of treatment and 6 months after 
the treatment), and for a sustained virologic response 
was considered an undetectable level of HCV RNA in 
the blood, 24 weeks after completion of therapy. 
Before the start of the study, the protocol, 
informed consent and other accompanying documents 
were reviewed and approved by the Ethics Committee 
for Research over Humans at the UKIM Medical 
Faculty Skopje. Patients signed written informed 
consent for participation in the study, which was 
conducted in accordance with the Declaration of 
Helsinki. 
 
Statistical analysis 
The obtained data were processed with 
statistical computer program SPSS 17 for Windows. 
Various statistical tests were used, such as: 
- descriptive statistics (arithmetic mean, 
standard deviation, standard error, median and 
interquartile interval) for a description of quantitative 
features, 
- frequencies and percentages for a 
description of categorical features, 
- independent parametric and nonparametric 
tests (Student t-test for independent samples, Chi-
square test, Fisher exact test, Mann-Whitney test) 
were used to compare the analysis groups, 
- for comparison of the analysed parameters 
in the analysed period, dependent parametric and 
nonparametric tests were used (Student t-test for 
dependent samples, Wilcoxon Matched Pairs test, 
ANOVA Repeated-measurements, Friedman ANOVA 
test), 
- for all analyses, the value of < 0.05 was 
considered statistically significant, and p < 0.01 for 
highly significant. 
 
 
Results 
 
The results of our study showed a non-
significant difference between the groups before the 
treatment regarding the gender, age, drug abuse, the 
genotypic distribution, viral load, histology activity 
index, presence of fibrosis and steatosis, 
transaminase activity, lipid and carbohydrate status. 
Table 1 shows all the baseline characteristics of the 
whole group, of both analysed patient groups, and the 
comparison of the two groups. 
Table 1: Baseline characteristics and comparison between two 
groups of patients with CHC treated with or without 
atorvastatin + antiviral therapy 
Variable N (%) Group I n (%) Group II n (%) P value 
Gender, n% 
Male  50 (71.43) 27 (77.14) 23 (65.71)  
A
0.29 Female  20 (28.57) 8 (22.86) 12 (34.29) 
Age, years, mean ± SD 
 70 36.37 ± 7.7 36.23 ± 9.1 
B
0.94 
Drug abuse, n (%) 
Yes  40 (57.14) 23 (65.71) 17 (48.57)  
A
0.15 No  30 (42.86) 12 (34.29) 18 (51.43) 
Genotype n (%) 
Subtype 1 22 (31.43) 10 (28.57) 12 (34.29)  
Subtype 2 1 (1.43) 0 1 (2.86) Fisher exact, 
Subtype 3 46 (65.71) 24 (68.57) 22 (62.86) 0.7 
Subtype 4 1 (1.43) 1 (2.86) 0 
Viral load, n% 
Low  37(52.86) 20 (57.14) 17 (48.57)  
A
0.47 High  33 (47.14) 15 (42.86) 18 (51.43) 
Liver biopsy Knodell HAI, n % 
1  12 (17.91) 6 (17.65) 6 (18.18)  
2 22 (32.84) 13 (38.24) 9 (27.27)  
3 13 (19.4) 8 (23.53) 5 (15.15)  
4 11 (16.42) 5 (14.71) 6 (18.18)  
5 4 (5.97) 1 (2.94) 3 (9.09) 
C
0.24 
6 1 (1.49) 0 1 (3.03)  
7 1 (1.49) 0 1 (3.03)  
9 1 (1.49) 1 (2.94) 0  
11 1 (1.49) 0 1 (3.03)  
18 1 (1.49) 0 1 (3.03)  
Presence of fibrosis, n% 
No fibrosis  50 (71.43) 28 (80) 22 (62.86) Fisher exact, 
0.165 Fibrosis present 17 (24.29) 7 (20) 10 (28.57) 
Cirrhosis 3 (4.29) 0 3 (8.57)  
Steatosis, n% 
No steatosis  32 (45.71) 14 (40) 18 (51.43) Fisher exact, 
0.6 Mild 34 (48.57) 19 (54.29) 15 (42.86) 
Severe 4 (5.71) 2 (5.71) 2 (5.71)  
BMI, mean ± SD 
 25.52±4.4 25.77 ± 4.2 25.27 ± 4.6 
B
0.64 
AST (10-34 U/L), mean ± SD 
  72.53±75.2 63.6 ± 45.3 81.46 ± 96.3 
C
0.44 
ALT (10-45 U/L), mean ± SD 
  108.86±89.7 99.97 ± 68.9 117.7 ± 106.8 
C
0.73 
Trigliceride (0.0-2.0 mmol/L), mean ± SD 
  1.15 ± 0.6 1.17 ± 0.6 1.14 ± 0.6 
C
0.9 
Total Cholesterol (0.0-5.5 mmol/L), mean ± SD 
 4.27 ± 1.1 4.16 ± 1.3 4.38 ± 0.9 
C
0.41 
HDL-C (0.9-2.0 mmol/L), mean ± SD 
  1.15 ± 0.3 1.12 ± 0.3 1.17 ± 0.3 
C
0.5 
LDL-C (2.2-3.7 mmol/L), mean ± SD 
 2.54 ± 0.96 2.47 ± 1.1 2.61 ± 0.8 
C
0.53 
Fasting glucose (3.6-6.5 mmol/L), mean ± SD 
  5.38 ± 0.7 5.35 ± 0.7 5.41 ± 0.7 
C
0.7 
Fasting insulin (2-17 µiu/ml), mean ± SD 
  12.45 ± 10.8 12.95 ± 11.1 11.98 ± 10.7 
C
0.72 
HOMA-IR, mean ± SD 
  2.96 ± 2.7 3.12 ± 3.04 2.81 ± 2.5 
C
0.67 
Group I (with Atorvastatin); group II (without Atorvastatin). 
 
The virological response was determined after 
12 weeks of treatment (early virologic response, 
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EVR), at the end of treatment (end of treatment 
response, ETR), and 6 months after treatment 
(sustained virologic response, SVR) (Table 2). 
Table 2: Virologic response 
Variable N (%) Group I 
N (%) 
Group II 
N (%) 
P value 
Virologic response ЕVR 
Yes  45(93.75) 22 (95.65) 23 (92) Fisher exact, p = 
1.0 No  (36.25) 1 (4.35) 2 (8) 
Virologic response ЕTR 
Yes 53(85.48) 25 (89.29) 28 (82.35) Fisher exact, p = 
0.49 No 9(14.52) 3 (10.71) 6 (17.65) 
Virologic response SVR 
Yes 56(80) 30 (85.71) 26 (74.29) P = 0.23 
No 14(20) 5 (14.29) 9 (25.71) 
Group I (with Atorvastatin), group II (without Atorvastatin); p (Chi-square test): EVR (early 
virologic response-12 week of the beginning of therapy); ЕТR (end of virologic treatment 
response); SVR (sustained virologic response – 6 months after the end of treatment). 
 
The early virologic response resulted in 45 
(93.75%) patients, 22 of those (95.65%) were in the 
Atorvastatin group, and 23 (92%) were in the group 
without anti-lipemic therapy. End of treatment 
response resulted in 53 (85.48%) patients, 25 of those 
(89.29%) were in the Atorvastatin group, and 28 
(82.35%) were in the atorvastatin-free group; and 
sustained virological response, respectively, was 
achieved in 56 (80%) patients, 30 of those (85.71%) 
were in the anti-lipemic therapy group, and 26 
(74.29%) were in the group without additional anti-
lipemic therapy. The statistical analysis showed the 
non-significant difference between the group taking 
anti-lipemic therapy and the group not taking anti-
lipemic therapy, all in co-relation to the frequency of 
early virological response (p = 1.0), end of treatment 
virological response (p = 0.49) and 6 months after the 
treatment (p = 0.23). 
In the group of participants receiving 
Atorvastatin, a sustained virologic response was 
achieved significantly more frequently in patients with 
genotype 3 compared to those with genotype 1 
(95.83% vs 60%, p = 0.019), Table 3. 
Table 3: Virologic response 6 months after the treatment 
HCV genotype in pts 
with Atorvastatin 
SVR 
n (%) 
NVR 
n (%) 
P value 
1 6 (60) 4 (40) Fisher exact, 
P = 0.019* 3 23 (95.83) 1 (4.17) 
SVR (sustained virologic response); NVR (no virologic response); *p < 0.05. 
 
Figure 1 shows the difference between the 
rate of achieved SVR, depending on the type of 
therapy, as well genotype 1 and 3, whereas although 
the statistical analysis did not confirm a significant 
difference (p = 0.7, p = 0.34) between the groups, the 
rate of achieved SVR (95.83%) in the group of 
patients with genotype 3 who received Atorvastatin is 
remarkable. 
Table 4 shows the values of cholesterol, HDL, 
LDL, TG in three points (before treatment, at the end 
of treatment and 6 months after treatment) in both 
groups of participants. 
Before the start of the treatment, the two 
groups of subjects had non-significantly different 
cholesterol level values (p = 0.41). At the end of the 
treatment, in the group of patients receiving additional 
antilipemic therapy, significantly lower cholesterol 
values were measured compared to the standard 
therapy treatment group. (p = 0.0008). Even after 6 
months of completed treatment, patients who received 
Atorvastatin in addition to antiviral therapy had 
significantly lower cholesterol values than patients 
receiving only antiviral therapy (p = 0.038). 
 
Figure 1: SVR (sustained virologic response) NVR (no virologic 
response) group I (with Atorvastatin), group II (without Atorvastatin) 
 
Before the start of the treatment, participants 
from the two groups had non-significantly different 
values of HDL (p = 0.5). For a value of p = 0.02, a 
significant difference in HDL level values at the end of 
the treatment between the groups was confirmed. In 6 
months after completed treatment, differences in HDL 
level values between the two groups remain 
statistically non-significant (p = 0.36). 
Table 4: Cholesterol, HDL, LDL, TG in three points (before 
treatment, at the end of treatment and 6 months after 
treatment) in both groups of participants 
 Group II 
N Mean ± SD N Mean ± SD P value 
Cholesterol (mmol/l)     
 
BT 35 4.16 ± 1.3 35 4.38 ± 0.9 
A
0.41 
ET 35 3.83 ± 1.3 35 4.43 ± 0.7 
B
0.0008** 
AT 35 4.47 ± 1.4 35 4.89 ± 1.1 
B
0.038* 
HDL (mmol/l)     
 
BT 35 1.12 ± 0.3 35 1.17 ± 0.3 
A
0.5
 
ET 35 0.97± 0.3 35 1.1 ± 0.3 
B
0.02* 
AT 35 2.0 ± 0.35 35 1.2 ± 0.2 
B
0.36
 
LDL 
(mmol/l) 
    
 
BT 35 2.47 ± 1.1 35 2.61 ± 0.8 
A
0.53
 
ET 35 2.16 ± 1.1 35 2.56 ± 0.6 
A
0.06
 
AT 35 2.77 ± 1.2 35 3.04 ± 1.1 
A
0.33
 
TG (mmol/l)     
 
BT 35 1.17 ± 0.6 35 1.14 ± 0.6 
B 
0.9
 
ET 35 1.39 ± 0.6 35 1.71 ± 2.3 
B 
0.8
 
AT 35 1.32 ± 0.6 35 1.32 ± 0.7 
B 
0.9
 
Group I (with Atorvastatin), group II (without Atorvastatin); 
a 
(Student t test); 
b (
Mann-
Whitney test); *p < 0.05; **p < 0.01; BT - before treatment; ET-end of treatment; AT-after 
treatment (6 months). 
 
 
In the whole period of analysis, statistically 
non-significant differences were shown in the mean 
values of LDL level between the group of patients 
treated with and without Atorvastatin (p > 0.05). 
The differences between the two groups in 
terms of baseline (pre-therapy) and TG control values 
(at the end and 6 months after therapy) were 
statistically non-significant (p = 0.9, p = 0.8, p = 0.9 
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respectively). 
Table 5 presents the values of fasting 
glucose, fasting insulin and HOMA IR in three points 
(before treatment, at the end of treatment and 6 
months after treatment), in both groups of participants 
Table 5: Fasting glucose, fasting insulin and HOMA IR in three 
points (before treatment, at the end of treatment and 6 months 
after treatment), in both groups of participants 
 Group II 
N Mean ± SD N Mean ± SD P value 
Fasting glucose 
(mmol/L) 
    
 
BT 35 5.35 ± 0.7 35 5.41 ± 0.7 
A
0.7 
ET 35 4.92 ± 0.7 35 5.28 ± 0.8 
A
0.049* 
AT 35 5.19 ± 0.7 35 5.34 ± 0.6 
A
0.415 
Fasting insulin 
(mmol/L) 
    
 
BT 31 12.95 ± 11.1 35 11.98 ± 10.7 
B
0.72
 
ET 26 9.53 ± 7.6 35 15.15 ± 10.9 
A
0.032* 
AT 25 13.55 ± 10.6 35 10.86 ± 7.4 
A
0.33
 
HOMA IR     
 
BT 31 3.12 ± 3.04 35 2.81 ± 2.5 
B 
0.67
 
ET 26 2.15 ± 2.1 35 3.51 ± 3.4 
B 
0.01*
 
AT 25 3.19 ± 2.7 35 2.38 ± 1.7 
B 
0.45
 
Group I (with Atorvastatin), group II (without Atorvastatin); 
a 
(Student t test); 
b(
Mann-
Whitney test); *p < 0.05; BT-before treatment; ET-end of treatment; AT-after treatment (6 
months). 
 
Before the start of the therapy, there was no 
significant difference in the average values of fasting 
glucose between group I and group II (p = 0.7). At the 
end of the treatment, the average fasting glucose 
values were significantly lower in the group of patients 
who, in addition to standard antiviral therapy, received 
antilipemic therapy (4.92 ± 0.7 vs 5.28 ± 0.8; p = 
0.049), while control values after 6 months of 
completed treatment were non-significantly lower 
(5.19 ± 0.7 Sun 5.34 ± 0.6; p = 0.415). 
Values of fasting insulin before treatment start 
were non-significantly different between the two 
groups of patients (p = 0.72). At the end of the 
treatment, in the group with Atorvastatin, mean fasting 
insulin values were of 9.53 ± 7.6, which were 
significantly lower compared to the group without 
Atorvastatin, where mean values were of 10.86 ± 7.4 
(p = 0.032).  
Six months after the completed treatment 
program, non-significantly higher mean fasting insulin 
values were evaluated in the Atorvastatin group 
compared to the group without antilipemic therapy (p 
= 0.33). 
Both groups of participants had non-
significantly different values of the HOMA-IR index 
before the start of the treatment and 6 months after 
the treatment (p = 0.67, p = 0.45 consequently), and 
significantly different at the end of the treatment (p = 
0.01). In a group, I at the end of the treatment, 
significantly lower values for HOMA IR was obtained, 
in contrary to group II. 
Table 6 shows the distribution of the 
frequency of adverse events that occurred in patients 
during the treatment. 
 
 
Table 6: Distribution of the frequency of adverse events that 
occurred in patients during the treatment 
Side effects   Group I  
 N (%) 
 Group II  
 N (%) 
P value 
Thrombocytopenia  14 (40) 16 (45.7) 
A
0.63 
Leukopenia  17 (48.6) 18 (51.4) 
A
0.81 
Anemia 4 (11.4) 2 (5.7) 
B
0.34 
Flu like symptoms 12 (34.3) 4 (11,.4) 
A
0.023* 
Loss of appetite and weight loss 18 (51.4) 13 (37.1) 
A
0.23 
Hair loss  7 (20) 1 (2.9) 
B
0.027* 
Hypothyreosis 2 (5.7) 1 (2.9) 
B
0.5 
Hyperthyreosis 1 (2.9) 1 (2.9) 
B
0.75 
Nausea, vomitus 1 (2.9) 1 (2.9) 
B
0.75 
Fatigue, malaise  6 (17.1) 4 (11.4) 
B
0.49 
Cutaneous allergic reaction to 
the drug 
1 (2.9) 0 
B
0.5 
Dry skin  2 (5.7) 0 
B
0.25 
Vertigo 1 (2.9) 0 
B
0.5 
Infection 1 (2.9) 0 
B
0.5 
Anxiety 10 (28.6) 7 (20) 
A
0.4 
Depression 1 (2.9) 0 
B
0.5 
Skin changes 3 (8.6) 1 (2.9) 
B
0.31 
Headache 1 (2.9) 1 (2.9) 
B
0.75 
Insomnia 1 (2.9) 2 (5.7) 
B
0.5 
Group I (with Atorvastatin); group II (without Atorvastatin); 
a
p (Chi-square test); 
b
p (Fisher 
exact test); *p < 0.05. 
 
The most common adverse reaction in the 
group which was receiving Atorvastatin was reduced 
appetite and decreased body weight (51.4%), followed 
by leucopenia (48.6%) and thrombocytopenia (40%). 
Haematological alterations were the most common 
adverse reactions in the group treated with standard 
antiviral therapy only-leukopenia and 
thrombocytopenia (51.4%, 45.7% respectively). A 
statistically significant difference between the two 
groups of patients was confirmed only about the 
frequency of occurrence of flu-like symptoms (p = 
0.023) and hair loss (p = 0.027). Patients in the first 
group significantly more frequently had the 
appearance of flu-like symptoms and hair loss (34.3%, 
20% consequently), compared with the second group 
of participants (11.4%, 2.9% respectively). 
 
 
Discussion  
 
Statins that inhibit the enzyme on the 
mevalonate pathway, HMG CoA reductase, have 
shown to play an important action not only in fat 
metabolism but also in the modulation of hepatic 
steatosis and fibrosis, and are presumed to have an 
important anti-proliferative, anti-angiogenic and 
antioxidant effect, with a potentially protective action 
against the development of HCC. In vitro studies, 
such as studies of Ikeda et al., [26]; and Aiziki et al., 
[27], have clearly shown that the statins inhibit the 
replication of viral RNA, more likely by inhibiting 
geranylgeranylation of cellular proteins, rather than by 
inhibiting cholesterol synthesis, showing almost the 
same efficacy as the most potent clinical treatment. 
However, studies have shown that not all statins have 
the same impact. According to them, atorvastatin, 
fluvastatin and simvastatin have stronger anti-HCV 
activity, lovastatin moderate activity, and pravastatin 
does not possess such activity, although it inhibits 
HMG-CoA reductase. 
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In vitro study of Ikeda et al., have shown that 
statins can be used as adjuvant therapy for interferon 
as well, just as ribavirin together with interferon shows 
synergistic antiviral activity [28]. 
In vivo studies, however, showed different 
results. Statin monotherapy did not lead to an 
improvement in the virologic response, probably due 
to the synergistic effect of statins with interferon, as 
demonstrated in the study of O'Leary et al., [29]
 
and 
Forde KA et al., [30]. 
Most studies have analysed the effect of 
Fluvastatin on the virologic response, and the number 
of studies that analysed other statins is lower. There 
are studies that are potentiating the positive impact of 
Fluvastatin as an additional therapy of standard 
antiviral therapy over virologic response, especially for 
genotype 1, such as the study of Selic Kurincic et al., 
[31]. The study of Atsukawa et al., [32], showed the 
reduction of viral relapse in patients with genotype 1b, 
as well as the studies of Georgescu et al., [33], Sesaki 
et al., [34]
 
and Kondo et al., [35]. In contrary to those, 
Shavakhi et al., published results where additional 
therapy with Atorvastatin in patients with genotype 1 
over 12 weeks does not lead to a better SVR [36]. The 
study of Malaguarnera et al., showed that the use of 
Rosuvastatin has a significant influence over lipid 
metabolism, inflammatory status and fibrosis, but also 
no significantly improves the effect of standard 
therapy on the virologic response [37]. Тhe author Zhu 
et al., in his meta-analysis, concluded that additional 
statin therapy to previous standard IFN-α and ribavirin 
therapy improves SVR, RVR and EVR without 
additional adverse events and thus can be considered 
as an adjuvant treatment to IFN-α and ribavirin [38].  
Our results showed a higher percentage of 
the achieved sustained virologic response as a 
marker for the success of treatment in the statin group 
(85.71%) versus 74.29% of the SVR achieved in the 
antiviral therapy group only. But when we additionally 
made a comparison between Genotype 1 and 3 as the 
most common genotypes in our study, we obtained an 
even higher percentage of SVR achieved in genotype 
3 and combined treatment, of a high 95.83% versus 
83.36% achieved in genotype 3 and standard antiviral 
therapy. Although no significant difference has been 
obtained (p = 0.34), this is a remarkable result of a 
sustained virological response achieved in patients 
with genotype 3 (practically only one patient out of 23 
did not achieve SVR). This high percentage of 
virological response is achieving with the new direct 
antiviral drugs (DAA), mainly for other genotypes but 
not for genotype 3 [39], 40]. In the study of Sette H Jr 
et al., the rate of sustained virological response is 
lowest in patients with genotype 3, which is 90.7%, 
while in patients with genotype 1 it is 95.8%, in 
genotype 2 100%, and in genotype 4 also 100% [41]. 
Our results in the group of patients with genotype 1 
have also shown the difference between the two 
groups in terms of therapy, but in this case, we are 
talking about a much lower SVR rate (60% versus 
50%, p = 0.7). In the Atorvastatin group, patients with 
genotype 3 who have achieved sustained virological 
response are significantly higher, compared to 
patients with genotype 1, p = 0.019, which coincides 
with the conclusion of Zhu et al., in their meta-
analysis, that additional statin therapy should be used 
in other genotypes other than genotype 1, as in our 
case, in genotype 3. The early virological response 
(EVR) and end-of-treatment virologic response (ETR) 
analysis also showed that they were evident in a 
higher percentage in patients belonging to the statin 
group, 95.65% and 89.29%, compared to the patients 
put into the standard antiviral therapy group (92% and 
82.35%), but the comparison between the two groups 
of patients was statistically non-significant (p = 1.0 
and p = 0.49, respectively). 
Several parameters were analyzed in our two 
investigated groups (one group with antilipemic 
therapy, the other without it), and then compared to 
each other, such as: gender, age, genotype, the 
presence of steatosis, fibrosis and liver inflammation, 
body mass index, transaminase activity, but also more 
laboratory parameters that reflect the fat and sugar 
metabolism during antiviral therapy, actually before 
and after therapy. Differences between the two groups 
were observed about lipid and glucose status. 
Specifically, patients receiving additional anti-lipemic 
therapy had significantly lower total cholesterol levels 
at the end of treatment and 6 months after, compared 
to the other group (p = 0.0008 and p = 0.038). 
Significantly lower results were detected for HDL but 
only at the end of the treatment (p = 0.02), but higher 
mean value 2.0 ± 0.35 and p = 0.36 was observed 6 
months later, and the results for LDL were non-
significantly lower (p = 0.06 and p = 0.33). 
Considering this lipid profile, we can conclude that 
antiviral therapy supplemented with Atorvastatin, 
leads to a decrease in total cholesterol and LDL 6 
months after treatment, and an increase in HDL 
levels. According to these results, patients who 
received statins with antiviral therapy will have fewer 
chances to suffer from cardiovascular disease. 
About the glucose status, statistically 
significantly lower values of fasting glucose, fasting 
insulin, and HOMA IR index at the end of therapy in 
the Atorvastatin group were obtained, p = 0.049, p = 
0.032 and p = 0.01 respectively. This result suggests 
that additional statin therapy does not lead to a 
worsening of fasting glucose values and insulin 
resistance, as written in some studies [42], but rather 
to their improvement. This improvement in the glucose 
profile may also be due to the achieved sustained 
virological response in 85.71% of treated patients with 
Atorvastatin and antiviral therapy, thereby reversing 
the diabetogenic effect of the virus, as confirmed in 
other studies [43], [44]. Improving glucose status 
means reducing the chance of developing fibrosis and 
more advanced form of liver disease. Other 
parameters (gender, age, genotype, presence of 
steatosis, fibrosis, degree of inflammatory activity, and 
Todorovska et al. Atorvastatin in Combination with Pegylated Interferon and Ribavirin in Patients with Genotype 3 Hepatitis C Virus 
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transaminase activity) compared between the two 
groups did not show significant differences. 
The safety profile of drugs is also of particular 
importance. Adverse events commonly occurring in 
both groups were: decreased appetite and decreased 
body weight, leucopenia, thrombocytopenia, flu-like 
symptoms, anxiety, fatigue and malaise, anaemia, 
hair loss, thyroid disorders, and others. In one patient 
due to a skin allergic reaction, therapy with peg-IFN 
α2a was discontinued and started with peg-IFN α2b 
after which there were no side effects, and the 
treatment was completed according to the genotype 3 
protocol. In the remaining patients, adverse events 
were not life-threatening and were not a cause for 
discontinuation of therapy. In our study, a statistically 
significant difference between the group of patients 
with Atorvastatin and without was confirmed only 
about the frequency of occurrence of flu-like 
symptoms (p = 0.023) and hair loss (p = 0.027). 
These symptoms lasted for short period of time and 
were reversible, indicating that statins can be safely 
used in patients with chronic hepatitis C. Verpaalen et 
al., in their review writes about the positive impact of 
statins in the treatment of HCV infection, but also their 
excellent safety profile and low cost [45], which 
coincides with our conclusions. 
In our study, the influence of statins on the 
progression of fibrosis, cirrhosis and the occurrence of 
HCC was not analysed. But since the goal of antiviral 
therapy is precisely preventing the onset of cirrhosis 
and HCC in this group of patients, we should not 
underestimate the significance of the statins in this 
field. Simon TG et al., in their review, indicates the 
association of atorvastatin and fluvastatin with a dose-
dependent reduction in the incidence of cirrhosis and 
HCC in patients with HCV infection [46]. We should 
consider all those facts when planning a strategy for 
the treatment of patients with Chronic Hepatitis C. 
In conclusion: 1) Combined therapy of 
Atorvastatin + Pegylated interferon alfa + Ribavirin 
leads to a high rate of sustained virological response 
of 95.83%, in patients with chronic hepatitis C, 
genotype 3; 2) Combined therapy leads to an 
improvement in lipid and glucose status after the 
treatment; and 3) Adverse events do not differ 
between the Atorvastatin group and the standard 
antiviral therapy group and do not lead to 
discontinuation of therapy. Therefore, statins can be 
safely used in patients with chronic hepatitis C. 
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